ArticleCancers2021

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough.

Veronica Mollica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.